Intraoral Administration of Botulinum Toxin for Continuous Dentoalveolar Neuropathic Pain: A Case Series

Aims: To lerability of intraoral administration of onabotulinum toxin A (BoNT/A) in patients suffering from intractable continuous dentoalveolar neuropathic pain. Methods: Eight patients (six women and two men) of ages ranging from 21 to 73 years (mean [standard deviation] 52.4 [16.1] years) suffering from continuous dentoalveolar pain for a mean duration of 5.8 (4.4) years received a submucosal injection of 10 to 25 units of BoNT/A into the vestibular mucosa surrounding the painful site. Pain intensity levels were recorded using a verbal rating scale (VRS). Safety and tolerability of BoNT/A were measured based on patient self-report, including any adverse effects reported by the patient at the injection site. Results: Five of eight patients reported positive pain reduction. In this group, mean pain intensity on a 0–10 VAS was 4.8 (2.2) at baseline and 2.6 (2.1) at postinjection. The analgesic effect was maximal between 7 and 14 days postinjection and lasted for 1 to 8 weeks before subsequently returning to the pre-injection levels. No adverse effects were reported at the injection sites. One patient noted transient partial hemi- facial paralysis. Conclusion: These results suggest the potential therapeutic benefit of BoNT/A in the management of continuous dentoalveolar neuropathic pain. Further investigations conducted via well-controlled studies in the area of orofacial pain are warranted. J Oral Facial Pain Headache 2019;33:160–164.

chronic pain;continuous neuropathic pain;dentoalveolar neuropathic pain;onabotulinum toxin A;orofacial pain

1. Pavone F, Luvisetto S. Botulinum neurotoxin for pain manage- ment: Insights from animal models. Toxins (Basel) 2010;2: 2890–2913.

2. Dolly JO, O’Connell MA. Neurotherapeutics to inhibit exocyto- sis from sensory neurons for the control of chronic pain. Curr Opin Pharmacol 2012;12:100–108.

3. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous admin- istration of botulinum toxin A reduces formalin-induced pain. Pain 2004;107:125–133.

4. Luvisetto S, Marinelli S, Lucchetti F, et al. Botulinum neurotox- ins and formalin-induced pain: Central vs. peripheral effects in mice. Brain Res 2006;1082:124–131.

5. Bach-Rojecky L, Lackovic´ Z. Antinociceptive effect of botuli- num toxin type a in rat model of carrageenan and capsaicin induced pain. Croat Med J 2005;46:201–208.

6. Marinelli S, Luvisetto S, Cobianchi S, et al. Botulinum neuro- toxin type A counteracts neuropathic pain and facilitates func- tional recovery after peripheral nerve injury in animal models. Neuroscience 2010;171:316–328.

7. Bach-Rojecky L, Relja M, Lackovic´ Z. Botulinum toxin type A in experimental neuropathic pain. J Neural Transm (Vienna) 2005;112:215–219.

8. Park HJ, Lee Y, Lee J, Park C, Moon DE. The effects of botuli- num toxin A on mechanical and cold allodynia in a rat model of neuropathic pain. Can J Anaesth 2006;53:470–477.

9. Bach-Rojecky L, Salkovic´-Petrisic´ M, Lackovic´ Z. Botulinum toxin type A reduces pain supersensitivity in experimental dia- betic neuropathy: Bilateral effect after unilateral injection. Eur J Pharmacol 2010;633:10–14.

10. Filipovic´ B, Bach-Rojecky L, Lackovic´ Z. Lasting reduction of postsurgical hyperalgesia after single injection of botulinum toxin type A in rat. Fundam Clin Pharmacol 2010;24:43–45.

11. Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 2008;28:3689–3696.

12. Klein AW. The therapeutic potential of botulinum toxin. Dermatol Surg 2004;30:452–455.

13. Relja M, Telarovic´ S. Botulinum toxin in tension-type headache. J Neurol 2004;251(suppl 1):112–114.

14. Miller D, Richardson D, Eisa M, Bajwa RJ, Jabbari B. Botulinum neurotoxin-A for treatment of refractory neck pain: A random- ized, double-blind study. Pain Med 2009;10:1012–1017.

15. Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50:921–936.

16. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol 2015;14:162–173.

17. International Association for the Study of Pain (IASP). IASP Terminology. IASP, 2017. http://www.iasp-pain.org/Education/ Content.aspx?ItemNumber=1698&navItemNumber=576. Accessed 16 November, 2018.

18. Okeson JP. Bell’s Oral and Facial Pain, ed 7. Chicago: Quintessence, 2014.

19. De Leeuw R. Orofacial Pain: Guidelines for Assessment, Diagnosis, and Management, ed 5. Chicago: Quintessence, 2013.

20. Nixdorf DR, Drangsholt MT, Ettlin DA, et al. Classifying oro- facial pains: A new proposal of taxonomy based on ontology. J Oral Rehabil 2012;39:161–169.

21. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33:629–808.

22. Herrero Babiloni A, Kapos FP, Nixdorf DR. Intraoral adminis- tration of botulinum toxin for trigeminal neuropathic pain. Oral Surg Oral Med Oral Pathol Oral Radiol 2016;121:e148–e153.

23. Cuadrado ML, García-Moreno H, Arias JA, Pareja JA. Botulinum neurotoxin type-A for the treatment of atypical odon- talgia. Pain Med 2016;17:1717–1721.

24. Moreau N, Dieb W, Descroix V, Svensson P, Ernberg M, Boucher Y. Topical review: Potential use of botulinum toxin in the management of painful posttraumatic trigeminal neuropa- thy. J Oral Facial Pain Headache 2017;31:7–18.

25. Attal N, de Andrade DC, Adam F, et al. Safety and effica- cy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): A randomised, double-blind, placebo controlled trial. Lancet Neurol 2016;15:555–565.

26. Baad-Hansen L, Benoliel R. Neuropathic orofacial pain: Facts and fiction. Cephalalgia 2017;37:670–679.